Statin intolerance

Current Opinion in Lipidology

Volumn 26, Issue 6, 2015, Pages 492-501

  Laufs, Ulrich ^a   Scharnagl, Hubert ^b   März, Winfried ^b,c,d  

^a SAARLAND UNIVERSITY   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d SYNLAB ACADEMY   (Germany)

Author keywords

HMG CoA reductase inhibitors; low density lipoprotein cholesterol; statin associated muscle symptoms; statin intolerance

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; SUBTILISIN;

CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG MEGADOSE; HUMAN; INCIDENCE; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MEDICATION COMPLIANCE; MOLECULAR PATHOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHABDOMYOLYSIS; STATIN ASSOCIATED MUSCLE SYMPTOM; CHEMICALLY INDUCED; MUSCULAR DISEASES; NOMENCLATURE; SAFETY; TIME FACTOR;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; SAFETY; TERMINOLOGY AS TOPIC; TIME FACTORS;

EID: 84952658193     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000236     Document Type: Review

References (103)

1. Fulcher J, O'Connell R, Voysey M, et al., Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 2015; 385:1397-1404.
2. Reiner Z, Catapano AL, De Becker G, et al., European Association for Cardiovascular Prevention and Rehabilitation. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769-1818.
3. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. J Am Coll Cardiol 2015; 65:1552-1561.
4. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease. the Framingham study. Ann Intern Med 1971; 74:1-12.
5. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129:S1-45.
6. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy: European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015; 36:1012-1022.
7. Virchow R. Der atheromatöse Prozess der Arterien. Wiener Medizinische Wochenschrift 1856; 52:825-827.
8. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005; 19:403-414.
9. Laufs U, Rettig-Ewen V, Böhm M. Strategies to improve drug adherence. Eur Heart J 2011; 32:264-268.
10. Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statininduced myotoxicity. Clin Pharmacol Ther 2014; 96:470-476.
11. Banach M, Rizzo M, Toth PP, et al. Statin intolerance: an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015; 11:1-23.
12. Keen HI, Krishnarajah J, Bates TR, Watts GF. Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century? Expert Opin Drug Saf 2014; 13:1227-1239.
13. Vrablik M, Zlatohlavek L, Stulc T, et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res 2014; 63 (Suppl 3):S327-334.
14. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a populationbased retrospective cohort study in Israel. Clin Ther 2008; 30:2167-2179.
15. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol 2012; 6:208-215.
16. Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and allcause mortality: a population-based cohort study. Arch Intern Med 2009; 169:260-268.
17. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288:462-467.
18. Bitzur R, Cohen H, Kamari Y, Harats D. Intolerance to statins: mechanisms and management. Diabetes care 2013; 36 (Suppl 2):S325-330.
19. Buettner C, Davis RB, Leveille SG, et al. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 2008; 23:1182-1186.
20. Buettner C, Rippberger MJ, Smith JK, et al. Statin use and musculoskeletal pain among adults with and without arthritis. Am J Med 2012; 125:176-182.
21. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Iinternal Med 2013; 158:526-534.
22. Kearney PM, Blackwell L, Collins R, et al., Cholesterol Treatment Trialists Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371:117-125.
23. Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J 2014; 168:6-15.
24. Heart Protection Study Collaborative G. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
25. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114:2788-2797.
26. Newman CB, Tobert JA. Statin intolerance: reconciling clinical trials and clinical experience. JAMA 2015; 313:1011-1012.
27. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207.
28. Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statin-related myalgia. Ann Intern Med 2014; 160:301-310.
29. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation 2013; 127:96-103.
30. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf 2011; 10:373-387.
31. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013; 29:1553-1568.
32. Cho L, Rocco M, Colquhoun D, et al. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol 2014; 37:131-139.
33. Moriarty PM, Jacobson TA, Bruckert E, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clini Lipidol 2014; 8:554-561.
34. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308:2497-2506.
35. Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother 2013; 47:398-404.
36. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013; 166:597-603.
37. Stein EA, Ballantyne CM, Windler E, et al. Efficacy and tolerability of fluvastatin XL 80mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol 2008; 101:490-496.
38. Goto Y. AFCAPS/TexCAPS (The Air Force/Texas Coronary Atherosclerosis Prevention Study). Nihon rinsho 2001; 59 (Suppl 3):398-403.
39. Law M, Rudnicka AR. Statin safety: a systematic review. Ame J Cardiol 2006; 97:52C-60C.
40. Armitage J. The safety of statins in clinical practice. Lancet 2007; 370:1781-1790.
41. Madsen CS, Janovitz E, Zhang R, et al. The Guinea pig as a preclinical model for demonstrating the efficacy and safety of statins. J Pharmacol Exp Ther 2008; 324:576-586.
42. Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol 2013; 62:709-714.
43. Naba H, Kakinuma C, Ohnishi S, Ogihara T. Improving effect of ethyl eicosapentanoate on statin-induced rhabdomyolysis in Eisai hyperbilirubinemic rats. Biochem Biophysi Res Comm 2006; 340:215-220.
44. Needham M, Mastaglia FL. Statin myotoxicity: a review of genetic susceptibility factors. Neuromuscul Disord 2014; 24:4-15.
45. Obayashi H, Nezu Y, Yokota H, et al. Cerivastatin induces type-I fiber-, not type-II fiber-, predominant muscular toxicity in the young male F344 rats. J Toxicol Sci 2011; 36:445-452.
46. Sidaway J, Wang Y, Marsden AM, et al. Statin-induced myopathy in the rat: relationship between systemic exposure, muscle exposure and myopathy. Xenobiotica 2009; 39:90-98.
47. Zhang P, Verity MA, Reue K. Lipin-1 regulates autophagy clearance and intersects with statin drug effects in skeletal muscle. Cell Metab 2014; 20:267-279.
48. Hanai J, Cao P, Tanksale P, et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007; 117:3940-3951.
49. Mohaupt MG, Karas RH, Babiychuk EB, et al. Association between statinassociated myopathy and skeletal muscle damage. Can Med Assoc J 2009; 181:E11-18.
50. Urso ML, Clarkson PM, Hittel D, et al. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscl Thromb Vas 2005; 25:2560-2566.
51. Bersot T. Drug therapy for hypercholesterolemia and dyslipidemia. In: Brunton LLCB, Knollmann BC, editors. The Pharmacological Basis of Therapeutics, Goodman & Gilman's. 12 edition (January 10, 2011). New York: McGraw-Hill Professional; 2011. pp. 877-905.
52. Gong IY, Kim RB. Impact of genetic variation in OATP transporters to drug disposition and response. Drug Metab Pharmacokinet 2013; 28:4-18.
53. Knauer MJ, Urquhart BL, Meyerzu Schwabedissen HE, et al. Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010; 106:297-306.
54. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statinrelated myopathy. Arch Neurol 2005; 62:1709-1712.
55. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137:581-585.
56. Rodrigues AC. Efflux and uptake transporters as determinants of statin response. Expert Opin Drug Metab 2010; 6:621-632.
57. Sakamoto K, Kimura J. Mechanism of statin-induced rhabdomyolysis. J Pharmacol Sci 2013; 123:289-294.
58. Link E, Parish S, Armitage J, et al., Search Collaborative Group. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med 2008; 359:789-799.
59. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol 2005; 45:89-118.
60. Hoffman EP, Nader GA. Balancing muscle hypertrophy and atrophy. Nat Med 2004; 10:584-585.
61. Mallinson JE, Constantin-Teodosiu D, Sidaway J, et al. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol 2009; 587:219-230.
62. Gratsianskii NA. Statins as anti-inflammatory agents. Kardiologiia 2001; 41:14-26.
63. Wu JS, Buettner C, Smithline H, et al. Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications. Muscle Nerve 2011; 43:76-81.
64. Vladutiu GD, Tarnopolsky M, Baker S, et al. Inborn errors of muscle metabolism implicated in risk for statin-induced myopathy. Molec Genet Metab 2014; 111:264-265.
65. Mangravite LM, Engelhardt BE, Medina MW, et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 2013; 502:377-380.
66. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogeneti Genom 2006; 16:873-879.
67. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 2010; 87:130-133.
68. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011; 63:157-181.
69. Baker SK, Vladutiu GD, Peltier WL, et al. Metabolic myopathies discovered during investigations of statin myopathy. Can J Neurol Sci 2008; 35:94-97.
70. Carr DF, Alfirevic A, Johnson R, et al. GATM gene variants and statin myopathy risk. Nature 2014; 513:E1.
71. DeGorter MK, Tirona RG, Schwarz UI, et al. Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. Circ Cardiovas Genet 2013; 6:400-408.
72. Isackson PJ, Ochs-Balcom HM, Ma C, et al. Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS. Muscle Nerve 2011; 44:531-538.
73. Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis 2007; 6:7.
74. Ruano G, Windemuth A, Wu AH, et al. Mechanisms of statin-induced myalgia assessed by physiogenomic associations. Atherosclerosis 2011; 218:451-456.
75. Vladutiu GD, Isackson PJ, Kaufman K, et al. Genetic risk for malignant hyperthermia in nonanesthesia-induced myopathies. Mol Genet Metab 2011; 104:167-173.
76. Vladutiu GD, Simmons Z, Isackson PJ, et al. Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 2006; 34:153-162.
77. Tonelli M, Wanner C. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med 2014; 160:182.
78. Rosenson RS, Baker SK, Jacobson TA, et al. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014; 8:S58-71.
79. Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis 2010; 210:337-343.
80. Gertz K, Dreier JP, Endres M. The causes of statin induced myopathies. Der Nervenarzt 2005; 76:1006-1007.
81. Mancini GB, Baker S, Bergeron J, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Can J Cardiol 2011; 27:635-662.
82. Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatininduced myopathy. Clin Pharmacol Ther 2012; 92:112-117.
83. Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Intern 2014; 85:1303-1309.
84. Li DQ, Kim R, McArthur E, et al. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Can Med Assoc J 2015; 187:174-180.
85. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80:565-581.
86. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372:2387-2397.
87. Landray MJ, Haynes R, Hopewell JC, et al., HPS Thrive Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371:203-212.
88. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of coenzyme Q10 supplementation on statin-induced myalgias. Am J Cardiol 2012; 110:526-529.
89. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007; 99:1409-1412.
90. Fedacko J, Pella D, Fedackova P, et al. Coenzyme Q(10) and selenium in statin-associated myopathy treatment. Can J Physiol Pharm 2013; 91:165-170.
91. Glueck CJ, Budhani SB, Masineni SS, et al. Vitamin D deficiency, myositismyalgia, and reversible statin intolerance. Curr Med Res Opin 2011; 27:1683-1690.
92. Kurnik D, Hochman I, Vesterman-Landes J, et al. Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins. Clin Endocrinol 2012; 77:36-41.
93. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia: a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol 2015; 178:111-116.
94. Pfeifer M, Begerow B, Minne HW. Vitamin D and muscle function. Osteoporosis Int 2002; 13:187-194.
95. Riphagen IJ, van der Veer E, Muskiet FA, DeJongste MJ. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin 2012; 28:1247-1252.
96. Zlatohlavek L, Vrablik M, Grauova B, et al. The effect of coenzyme Q10 in statin myopathy. Neuro Endocrinol Lett 2012; 33 (Suppl 2):98-101.
97. Waber RL, Shiv B, Carmon Z, Ariely D. Commercial features of placebo and therapeutic efficacy. JAMA 2008; 299:1016-1017.
98. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363:2406-2415.
99. Davidson M, Liu SX, Barter P, et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res 2013; 54:467-472.
100. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011; 306:2099-2109.
101. Moriarty PM, Thompson PD, Cannon CP, et al. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus Ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm. latebreaking clinical trial abstracts and clinical science special reports abstracts from the American Heart Association's Scientific Sessions 2014. Circulation 2014; 130:2108-2109.
102. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1489-1499.
103. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500-1509.